Nicolas Zucchini

Dr. Nicolas Zucchini

S.S.D. Chirurgia dell'Obesità e Metabolica, Dipartimento di Chirurgia, Azienda Ospedaliera G. Brotzu, Cagliari, Sardegna, Italy
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2025 in Surgical Endoscopy
Verified
Journal Article
Open access
PDF file
AMAlessandra Moretti
Alessandra Moretti
NZNicolas Zucchini
Nicolas Zucchini
EMEnrico Moroni
Enrico Moroni
DSDanilo Sirigu
Danilo Sirigu
DSDaniela Sanna
Daniela Sanna
GFGiovanni Fantola
Giovanni Fantola

15 June 2025 in Journal of Robotic Surgery
Verified
Journal Article
Closed access
PDF file
NZNicolas Zucchini
Nicolas Zucchini
CNCarlo Nagliati
Carlo Nagliati
GFGiovanni Fantola
Giovanni Fantola

27 August 2025 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
AMAlessandra Moretti
Alessandra Moretti
NZNicolas Zucchini
Nicolas Zucchini
EMEnrico Moroni
Enrico Moroni
DSDanilo Sirigu
Danilo Sirigu
DSDaniela Sanna
Daniela Sanna
GFGiovanni Fantola
Giovanni Fantola

9 October 2026 in Gastroenterology Insights
Verified
Journal Article
Open access
PDF file
Christian Adrian Macias ArguelloChristian Adrian Macias Arguello
Christian Adrian Macias Arguello
AGAman Goyal
Aman Goyal
PCPhillip Chehet
Phillip Chehet
FMFederico Maria Mongardini
Federico Maria Mongardini
NZNicolas Zucchini
Nicolas Zucchini
RORodolfo J Oviedo
Rodolfo J Oviedo
Background: Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are considered major causes of cancer-related mortality. Evidence suggests that gut microbiome dysbiosis and the microbial–metabolic axis and its metabolites in hepatic chronic inflammation might be implicated in carcinogenesis in the gut–liver axis. This descriptive systematic review examines the microbial–metabolic axis in hepatobiliary cancer, focusing on patterns of dysbiosis, microbiome-associated metabolites, and the diagnostic or prognostic potential in this field. Methods: This manuscript was developed according to PRISMA 2020 guidelines and registered in PROSPERO (CRD420261455009). PubMed, Scopus, Cochrane Library, Web of Science, and Embase were searched. Eligible studies were published medical manuscripts reporting gut (oral/duodenal/fecal) microbiome alterations with links to HCC or CCA. Risk of bias was assessed with Rob 2.0 for the randomized clinical trial study included in this manuscript and ROBINS-I for the non-randomized studies. Ultimately, 13 studies met the inclusion criteria and were included in this qualitative study. Results: In the included studies, patients with HCC or CCA showed altered gut microbial diversity, a depletion of beneficial taxa such as Faecalibacterium and Bifidobacterium, and increased levels of potentially pro-inflammatory genera. Specific signatures such as Alloprevotella and the B.F.R. genera models in CCA were associated with diagnostic performance, with AUCs that frequently exceeded 0.90 in internal validation. Furthermore, circulating and host microbial metabolites, such as methionine, methionine sulfoxide, taurocholic acid, and microbial-derived TMA/TMAO pathway components, were associated with HCC risk. Conclusions: According to our analysis, gut microbiome alterations are associated with HCC and CCA and show promising diagnostic and prognostic potential. The findings are consistent with a possible microbial–metabolic contribution to hepatocarcinogenesis through chronic inflammatory and metabolic pathways. However, most included studies evaluated virus-related liver disease, and direct evidence linking obesity or MASLD-related dysbiosis to hepatobiliary cancer remains limited. Prospective and interventional investigations of metabolic liver disease populations are needed to clarify this axis.

1 January 2026 in Intelligent Surgery
Verified
Journal Article
Open access
MKMichail Koutentakis
Michail Koutentakis
YPYuvraj G. Parmar
Yuvraj G. Parmar
ABAbhirami Babu
Abhirami Babu
VVVanessa Pamela Salolin Vargas
Vanessa Pamela Salolin Vargas
CBCarlos Felipe Bustillos
Carlos Felipe Bustillos
RORodolfo J Oviedo
Rodolfo J Oviedo

6 February 2026 in Endocrines
Verified
Journal Article
Open access
PDF file
NZNicolas Zucchini
Nicolas Zucchini
FCFrancesca Lo Celso
Francesca Lo Celso
AGAlice Gabrieli
Alice Gabrieli
CNClemente Junior Nappi
Clemente Junior Nappi
NBNicolò Bortolussi
Nicolò Bortolussi
GFGiovanni Fantola
Giovanni Fantola
Background: The interplay between obesity and thyroid dysfunction is complex, characterized by adaptive hyperthyrotropinemia and peripheral hormone resistance. Metabolic and Bariatric surgery (MBS) has emerged not only as a weight-loss (WL) intervention but also as a potent modulator of the thyroid–gut axis. Methods: We conducted a narrative review of the literature (2015–2025), synthesizing data from prospective cohorts, meta-analyses, and mechanistic studies to evaluate the impact of MBS on thyroid function, autoimmune dynamics, and drug pharmacokinetics. Discussion: Current evidence suggests that MBS promotes a recalibration of the thyroid axis. Post-operative WL is independently associated with a significant reduction in serum thyroid-stimulating hormone (TSH) and free triiodothyronine (fT3) levels, reversing obesity-induced peripheral resistance. Concurrently, the reduction in systemic inflammation (NOD-like receptor protein 3 (NLRP3) inflammasome deactivation) may dampen lymphocytic infiltration, while the amelioration of gut dysbiosis and intestinal permeability is hypothesized to reduce cross-reactivity mechanisms (molecular mimicry), leading to decreased antibody titers in Hashimoto’s thyroiditis. However, these benefits are counterbalanced by altered drug absorption mechanisms. While most hypothyroid patients benefit from reduced Levothyroxine (L-T4) requirements due to decreased lean mass, malabsorptive procedures (Roux-en-Y Gastric Bypass, One Anastomosis Gastric Bypass) can precipitate refractory hypothyroidism due to bypassed absorptive surfaces and altered gastric pH. Conclusions: MBS offers a dual benefit of functional restoration and modulation of autoimmune markers. However, post-surgical management requires a tailored approach. Clinicians must distinguish between the physiological decline in TSH (adaptive) and iatrogenic malabsorption, advocating for liquid L-T4 formulations in complex malabsorptive phenotypes.